Amgen Inc. (AMGN)
Health Care6 articles
Market Mood
Amgen (AMGN) Linked to 20 Deaths in Japan from Drug Usage
A reported 20 individuals in Japan have died following the administration of a drug developed by Amgen (AMGN). This incident raises concerns about the medication's safety and efficacy, potentially impacting Amgen's reputation and stock performance. Investors may closely monitor how this development influences regulatory scrutiny and market confidence in Amgen's products. These events could lead to increased volatility in AMGN shares as more information becomes available.
Read More
Amgen (AMGN) Stock Drops After Kissei's Tavneos Liver Risk Warning
Amgen (AMGN) experienced a decline in its stock price following a warning from Kissei Pharmaceutical regarding liver risks associated with Tavneos. Specific data on the stock price drop or percentage changes was not provided. This warning may lead to investor concerns about potential market implications for Amgen, particularly if regulatory actions arise due to safety assessments. Kissei's caution could also impact the competitive landscape for treatments related to liver conditions.
Read More
Amgen (AMGN) Reports 24% Growth Driven by Key Factors
Amgen (AMGN) announced a 24% expansion in Q1 2026, attributing this growth to six main drivers. This performance reflects a significant increase in demand and improved operational efficiencies. Such growth may positively influence market perceptions, especially among investors looking for robust earnings potential. Monitoring these growth drivers could help analysts assess Amgen's future performance and its impact on the biotechnology sector.
Read More
Amgen (AMGN) Q1 2026 Earnings Beat EPS Forecast
Amgen (AMGN) reported its Q1 2026 earnings, exceeding EPS forecasts. The company achieved earnings of $XYZ per share, surpassing analysts' expectations. Despite the earnings beat, AMGN's stock experienced a dip of X% following the announcement. This reaction may reflect investor concerns about future performance or guidance. The report suggests mixed sentiment among investors regarding Amgen's prospects.
Read More
Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Novartis (NVS), Amgen (AMGN), and Eli Lilly (LLY) are conducting late-stage trials for drugs aimed at reducing lipoprotein(a) or Lp(a) levels to prevent heart attacks. Current experimental drugs are shown to reduce Lp(a) by over 80%. Consensus estimates suggest these drugs could generate annual sales of $5.6 billion by 2032. The first results from Novartis' Phase 3 Horizon trial are expected later this year, which will significantly influence the market potential of these therapies.
Read More
Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy
Zai Lab (ZLAB) and Amgen (AMGN) have announced a partnership to evaluate a combination therapy for lung cancer. This collaboration is aimed at improving treatment options for patients and could signify advancements in oncology therapies. The outcomes of this evaluation may impact both companies' stock performance and the broader market perception of lung cancer treatments. Investors will be watching the developments closely given the increasing focus on cancer therapies within the biopharmaceutical sector.
Read More